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 2 
Abstract 16 
Diacylhydrazines are the first non-steroidal ecdysone agonists, and five compounds are 17 
used as insecticides in agriculture. After the discovery of diacylhydrazine-type 18 
compounds, numerous non-steroidal structures were reported as ecdysone agonists. 19 
Among various ecdysone agonists, imidazothiadiazoles are reported to be very potent in 20 
vitro; however the experimental detail for the structure identification and bioassays are 21 
not stated in the paper (Holmwood and Schindler, Bioorg. Med. Chem., 17, 4064-4070, 22 
2009). In our present study, we synthesized 18 imidazothiadiazole-type compounds and 23 
confirmed the chemical structures by spectrometric analyses. The binding activity of the 24 
synthesized compounds to the ecdysone receptor was evaluated in terms of the 25 
concentration required for 50% inhibition of [
3
H]ponasterone A incorporation [IC50 (M)] 26 
into lepidopteran (Sf-9), coleopteran (BCRL-Lepd-SL1), and dipteran (NIAS-AeAl2) 27 
cells. 6-(2-Chlorophenyl)-2-(trifluoro- methyl)imidazo[2,1-b] 28 
[1,3,4]-thiadiazolyl-5-yl)acrylamide analogs with –CONHR (secondary amide) were 29 
very potent against Sf-9 cells, but further alkylation (tertiary amide: –CONR2) decreased 30 
the activity dramatically. Additionally, a primary amide analog (–CONH2) was inactive. 31 
The activity also decreased 150-fold by the saturation of olefin region of the acrylamide 32 
moiety. In addition, various substituents were introduced at the 2-position of the 33 
imidazothiadiazole ring to disclose the physicochemical properties of the substituents 34 
which are important for receptor binding. The activity increased by 7500-fold with the 35 
introduction of the CF2CF2CF3 group compared to the unsubstituted compound against 36 
Sf-9 cells. Quantitative structure-activity relationship analysis for these substituents 37 
indicated that hydrophobic and electron-withdrawing groups were favorable for binding. 38 
Some of the compounds with strong receptor binding activity showed good larvicidal 39 
activity against Spodoptera litura. In contrast, the binding affinity of imidazothiadiazole 40 
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1. Introduction 47 
Arthropods, including insects, grow by repeated molting, which is regulated by 48 
molting hormones such as 20-hydroxyecdysone (20E; Fig. 1). Steroidal compounds with 49 
20E-like activity are categorized as ecdysteroids, and have been identified in plants, 50 
animals, and microorganisms. To date, more than 400 ecdysteroids have been 51 
characterized (http://ecdybase.org), but no ecdysteroids have been launched as 52 
insecticides. Using steroids as insecticides may not be practical because of their high cost 53 
and synthesis difficulty. In addition, steroids do not easily penetrate the integument and 54 
are rapidly excreted from insects.  55 
The discovery of diacylhydrazine (DAH)-type compounds (Fig. 1) enabled the 56 
development of novel ecdysone agonist insecticides [1, 2]. Currently, five DAHs, namely, 57 
tebufenozide, methoxyfenozide, chromafenozide, fufenozide, and halofenozide, are 58 
available on the market. These DAH-type compounds are generally used in agriculture 59 
against Lepidoptera, but halofenozide also shows control of Coloeoptera. 60 
 61 
Fig. 1 62 
 63 
Because the insecticidal spectrum of DAHs is narrow, other chemical structures 64 
have been screened as ecdysone agonists [3]. Among them, tetrahydroquinoline (THQ) 65 
[4], N-alkyl-3,5-di-tert-butyl-4-hydroxy-benzamide [5], -acylaminoketone [6], 66 
oxadiazoline [7], and -methylene--lactam [8] have been described over the past two 67 
decades. In 2009, Holmwood and Schindler reported that imidazole (IMD) and 68 
imidazothiadiazole (ITD)-type compounds are ecdysone agonists (Fig. 2) [9]. Although 69 
the biological activity was evaluated quantitatively in terms of pInd50 (EcR induction 70 
assay), experimental procedures and target insect species have not been described. 71 
Analytical data for the synthesized chemicals were not reported. 72 
The binding mode of IMD-type compounds was reported to be similar to that of 73 
DAHs based on crystal structure analysis. The binding mode of ITD-type compounds is, 74 
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however, thought to differ from those of DAHs and steroidal agonists such as ponasterone 75 
A (PonA). The ITD substructure is very interesting, because some ITD-type compounds 76 
are reported to show anti-inflamatory [10], anticancer [11] and antitubercular activity 77 
[12].  78 
The aim of this study was to quantitatively measure the ligand-receptor binding 79 
activity of ITD analogs and discuss the structure-activity relationship (SAR). For the 80 
SAR study, various ITD analogs were chemically synthesized. The substituents X at 81 
2-position of imidazothiadiazole ring (Fig. 2) were substituted with H, CH3, CF3, CF2CF3, 82 
CF2CF2CF3, SCH3, S(=O)CH3, SO2CH3, and the amide moiety to vary primary, 83 
secondary, and tertiary structure (Fig. 2). The linker between the imidazole ring and 84 
amide moiety was fixed as either trans -CH=CH- or -CH2CH2- (Fig. 2). Thioamide and 85 
sulfonamide analogs were also synthesized (Fig. 2). The binding affinity of these 86 
compounds was measured to the ecdysone receptors of three insect cells. The effect of 87 
substituents X on ligand-receptor binding against Sf-9 was quantitatively analyzed using 88 
classical quantitative structure-activity relationship (QSAR) analysis (Hansch-Fujita 89 
method) [13]. Docking simulation was also performed to predict the ligand-receptor 90 
interaction of ITDs. 91 
 92 
Fig. 2 93 
 94 
 95 
2. Materials and Methods 96 
2.1. Synthesis 97 
2.1.1. Chemicals 98 
Chemicals were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA), Tokyo 99 
Chemical Industry Co., Ltd. (Tokyo, Japan), Wako Pure Chemical Industries, Ltd. (Osaka, 100 
Japan), and Nacalai Tesque Inc. (Kyoto, Japan). Oven-dried glassware and positive argon 101 
pressure were used to maintain anhydrous conditions. Anhydrous solvents were 102 
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commercially available and stored over molecular sieves. Flash column chromatography 103 
was conducted using Wakogel
®
 C-300HG (Wako Pure Chemical Industries, Osaka, 104 
Japan) as the absorbent. NMR spectra were recorded on a Bruker AVANCE-400 or 105 
Bruker AVANCE-500 spectrometer. Tetramethylsilane was used as the internal standard 106 
for 
1
H NMR (0 ppm); deuterated solvent signals were used as the internal standard for 
13
C 107 
NMR (77.16 ppm for CDCl3 and 39.52 ppm for DMSO-d6); and α,α,α-trifluorotoluene 108 
was used as the external standard for 
19
F NMR (-64.00 ppm). Melting points were 109 
measured with a Yanaco melting point apparatus (Yanagimoto Seisakusho Co. Ltd., 110 
Kyoto, Japan) and are uncorrected. Elemental analyses were performed at the 111 
Microanalytical Center of Kyoto University. High-resolution mass spectra (HRMS) were 112 
recorded on a Thermo Fisher Scientific EXACTIVE spectrometer at Department of 113 
Synthetic Chemistry and Biological Chemistry of Kyoto University. 114 
 115 
2.1.2. Synthesis of 2-amino-1,3,4-thiadiazoles (Scheme 1) 116 
 117 
Scheme 1 118 
 119 
i) 2-Amino-5-(trifluoromethyl)-1,3,4-thiadiazole (Step a): Phosphoryl chloride (27.5 mL, 120 
300 mmol) was added dropwise to a mixture of thiosemicarbazide (13.7 g, 150 mmol) 121 
and trifluoroacetic acid (24.1 mL, 315 mmol) at 0°C, and the mixture was gradually 122 
heated to 70°C. Foaming was observed during the reaction. The mixture was kept at 70ºC 123 
for 1 hour after the foaming ceased. After cooling the reaction mixture to room 124 
temperature, it was treated with water (300 mL) and neutralized with saturated Na2CO3 125 
solution. The resulting solid was filtered off, washed with water and dried in vacuo to 126 
yield an off-white solid (19.4 g, 77%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.07 (2H, s) 127 
ppm; 
13
C NMR (100 MHz, DMSO-d6) δ 119.8 (q, JC-F = 269 Hz), 143.8 (q, JC-F = 37 Hz), 128 
171.7 ppm; 
19
F NMR (377 MHz, DMSO-d6) δ -59.77 (3F, s) ppm. 129 
2-Amino-1,3,4-thiadiazoles with CF2CF3 and CF2CF2CF3 group were synthesized in a 130 
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similar manner as above.  131 
 132 
ii) 2-Amino-5-(methylthio)-1,3,4-thiadiazole (Step b): Potassium hydroxide (85%, 3.4 g, 133 
51 mmol) was added in one portion to a suspension of 2-amino-5-mercapto- 134 
1,3,4-thiadiazole (6.7 g, 50 mmol) in 2-propanol (10 mL) and water (7.5 mL) at 0°C. 135 
When the starting materials completely dissolved, methyl iodide (3.3 mL, 53 mmol) was 136 
added dropwise to the reaction mixture maintaining the temperature below 15°C. It was 137 
stirred at room temperature overnight. The mixture was poured into water (200 mL) and 138 
the resulting solid was filtered off. This was washed with water and dried in vacuo to 139 
yield a white solid (5.6 g, 76%). 
1
H NMR (400 MHz, DMSO-d6) δ 2.58 (3H, s), 7.21 (2H, 140 
s) ppm; 
13
C NMR (100 MHz, DMSO-d6) δ 16.6, 151.9, 168.9 ppm. 141 
 142 
2.1.3. Synthesis of 2-chlorophenacyl bromide 143 
A solution of bromine (26.5 g, 166 mmol) in acetic acid (25 mL) was added dropwise to a 144 
solution of 2´-chloroacetophenone (25.1 g, 162 mmol) in acetic acid (175 mL) at room 145 
temperature. The mixture was stirred at room temperature for 2 hours. The mixture was 146 
diluted with water (250 mL) and extracted with CH2Cl2 (250 mL). The organic layer was 147 
washed successively with water (3×250 mL), saturated aqueous NaHCO3 solution (250 148 
mL) and brine (250 mL), and dried over anhydrous Na2SO4. The solvent was evaporated 149 
to give the crude 2-chlorophenacyl bromide (38.7 g, purity: ca. 83% determined by 
1
H 150 
NMR analysis), which was used for the next reaction without further purification. 151 
 152 
2.1.4. Synthesis of (E)-3-(6-(2-chlorophenyl)-imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 153 
acrylic acids (Scheme 2) 154 
 155 
Scheme 2 156 
 157 
i) 6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazole (Step a): A 158 
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mixture of 2-amino-5-(trifluoromethyl)-1,3,4-thiadiazole (19.2 g, 114 mmol) and 159 
2-chlorophenacyl bromide (33.4 g, ca. 120 mmol) in ethanol (170 mL) was refluxed 160 
overnight. The mixture was then cooled in a freezer. The resulting crystalline solid was 161 
filtered off, washed with cold ethanol, and dried in vacuo to yield a pale yellow solid 162 
(19.3 g, 56%). 
1
H NMR (400 MHz, DMSO-d6) δ 7.39 (1H, td, J = 7.9, 1.8 Hz), 7.47 (1H, 163 
td, J = 7.5, 1.3 Hz), 7.58 (1H, dd, J = 7.9, 1.3 Hz), 8.11 (1H, dd, J = 7.8, 1.8 Hz), 8.96 (1H, 164 
s) ppm. 165 
Other imidazothiadiazole analogs with CF2CF3, CF2CF2CF3, H, CH3, and SCH3 were 166 
synthesized in a similar manner as above. 167 
 168 
ii) 6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazole-5-carbalde- 169 
hyde (Step b):  Under an argon atmosphere, phosphoryl chloride (3.9 mL, 43 mmol) was 170 
added dropwise to anhydrous DMF (20 mL) at 0°C and stirred for 5 min. To this was 171 
added 6-(2-chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazole (3.91 g, 172 
13 mmol) in anhydrous DMF (15 mL), and the mixture was heated to 70°C and stirred 173 
overnight. It was poured into ice-water (100 mL), neutralized with saturated aqueous 174 
Na2CO3 solution and then extracted with toluene (1×100 mL, 2×50 mL). The combined 175 
organic layer was washed with water (3×100 mL) and brine (100 mL), and dried over 176 
anhydrous MgSO4. The solvent was evaporated and the crude product was purified by 177 
flash column chromatography (hexane/ethyl acetate = 95:5 – 50:50) to yield a pale yellow 178 
solid (2.91 g, 68%). 
1
H NMR (400 MHz, CDCl3) δ 7.43-7.49 (2H, m), 7.55-7.59 (2H, m), 179 
9.85 (1H, s) ppm. 180 
Other imidazothiadiazole-5-carbaldehyde analogs with CF2CF3, CF2CF2CF3, H, CH3, 181 
and SCH3 were synthesized in a similar manner as above. 182 
 183 
iii) (E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl) 184 
acrylic acid (Step c): 6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4] 185 
thiadiazole-5-carbaldehyde (2.01 g, 6.1 mmol) and piperidine (0.47 mL, 4.7 mmol) were 186 
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dissolved in pyridine (17 mL). To this, malonic acid (0.76 g, 7.3 mmol) was added and the 187 
mixture was stirred at 100°C for 4 h. After cooling, the reaction mixture was poured into 188 
1 M HCl (70 mL) and acidified with concentrated HCl. The resulting solid was filtered 189 
off, washed with water, and dried in vacuo. This solid was triturated in hexane/ether (1:1) 190 
to give an off-white solid (1.89 g, 84%). 
1
H NMR (400 MHz, DMSO-d6) δ 6.68 (1H, d, J 191 
= 16.0 Hz), 7.31 (1H, d, J = 16.0 Hz), 7.52-7.61 (3H, m), 7.67-7.71 (1H, m), 12.64 (1H, br. 192 
s) ppm. 193 
Other (imidazothiadiazol-5-yl)acrylic acid analogs with CF2CF3, CF2CF2CF3, H, CH3, 194 
and SCH3 were synthesized in a similar manner as above.  195 
 196 
2.1.5. Synthesis of (E)-3-(6-(2-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl) 197 
acrylamides (Scheme 3) 198 
 199 
Scheme 3 200 
 201 
 202 
i) (E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl) 203 
acrylamide (1): Oxalyl chloride (0.17 mL, 2.0 mmol) was added to the suspension of 204 
(E)-3-(6-(2-chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)acry-205 
lic acid (377 mg, 1.0 mmol) in CH2Cl2 (5 mL) containing one drop of DMF. After the gas 206 
evolution ceased, the mixture was refluxed for 2 hours. After cooling, the solvent was 207 
evaporated to give the crude acid chloride. This was dissolved in CH2Cl2 (5 mL), and then 208 
added dropwise to vigorously stirred aqueous NH3 solution (28%, 5 mL) at 0ºC. The 209 
mixture was stirred at room temperature overnight. It was diluted with water (30 mL) and 210 
extracted with CH2Cl2 (3×30 mL). The combined organic layer was washed with water 211 
(50 mL) and brine (50 mL), and dried over anhydrous Na2SO4. The solvent was 212 
evaporated and the crude product was recrystallized from ethyl acetate/hexane to give a 213 
white solid (276 mg, 73%). Mp: 232-234°C. 
1
H NMR (400 MHz, CDCl3) δ 5.67 (2H, br 214 
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s), 6.96 (1H, d, J = 15.6 Hz), 7.34-7.47 (3H, m), 7.51-7.58 (2H, m) ppm; 
13
C NMR (100 215 
MHz, CDCl3) δ 118.7 (q, JC-F = 272 Hz), 119.0, 122.9, 126.2, 127.2, 130.5, 130.9, 131.5, 216 
132.6, 134.0, 146.5, 148.5, 151.3 (q, JC-F = 42 Hz), 167.3 ppm; 
19
F NMR (377 MHz, 217 
CDCl3) δ -62.46 (3F, s) ppm. Anal. Calcd for C14H8ClF3N4OS: C, 45.11; H, 2.16; N, 218 
15.03. Found: C, 45.07; H, 2.20; N, 15.05. 219 
 220 
ii) (E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 221 
N-isopropylacrylamide (2): To a suspension of compound 12 (374 mg, 1.0 mmol) in 222 
anhydrous CH2Cl2 (5 mL), EDC hydrochloride (227 mg, 1.2 mmol) and catalytic amount 223 
of DMAP were added. Then, isopropylamine (98L, 1.2 mmol) was added and the 224 
mixture was stirred at room temperature overnight. The mixture was diluted with CH2Cl2 225 
(15 mL) and washed successively with saturated aqueous Na2CO3 solution, water, 1 M 226 
HCl, water, and brine (10 mL each). The organic layer was dried over MgSO4 and 227 
concentrated to give compound 17 as pale yellow foam (387 mg, 93%). This was further 228 
recrystallized from ethyl acetate/hexane to afford white crystals, which were used for the 229 
bioassays. Mp: 174-175°C. 
1
H NMR (400 MHz, CDCl3) δ 1.22 (6H, d, J = 6.6 Hz), 230 
4.14-4.27 (1H, m), 5.58 (1H, br d, J = 7.7 Hz), 6.86 (1H, d, J = 15.5 Hz), 7.33-7.45 (3H, 231 
m), 7.50-7.54 (2H, m) ppm; 
13
C NMR (100 MHz, CDCl3) δ 22.9, 41.9, 118.7 (q, JC-F = 232 
272 Hz), 120.6, 123.2, 124.6, 127.1, 130.5, 130.7, 131.6, 132.6, 134.1, 146.1, 148.0, 233 
151.0 (q, JC-F = 42 Hz), 164.6 ppm; 
19
F NMR (377 MHz, CDCl3) δ -62.43 (3F, s) ppm. 234 
Anal. Calcd for C17H14ClF3N4OS: C, 49.22; H, 3.40; N, 13.51. Found: C, 49.16; H, 3.59; 235 
N, 13.65. 236 
Other acrylamide analogs (3 - 13) were synthesized in a similar manner to that described 237 
for compound 2. Analytical data for the compounds are shown below. 238 
 239 
iii) (E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 240 
N-cyclobutylacrylamide (3): Mp: 199-200°C. 
1
H NMR (400 MHz, CDCl3) δ 1.69-1.78 241 
(2H, m), 1.88-2.00 (2H, m), 2.34-2.43 (2H, m), 4.51 (1H, quin, J = 8.1 Hz), 5.92 (1H, br d, 242 
 11 
J = 7.7 Hz), 6.86 (1H, d, J = 15.5 Hz), 7.33-7.44 (3H, m), 7.50-7.54 (2H, m) ppm; 
13
C 243 
NMR (100 MHz, CDCl3) δ 15.3, 31.4, 45.2, 118.7 (q, JC-F = 272 Hz), 120.3, 123.2, 124.9, 244 
127.1, 130.5, 130.8, 131.6, 132.6, 134.1, 146.2, 148.1, 151.0 (q, JC-F = 42 Hz), 164.5 245 
ppm; 
19
F NMR (377 MHz, CDCl3) δ -62.43 (3F, s) ppm. Anal. Calcd for 246 
C18H14ClF3N4OS: C, 50.65; H, 3.31; N, 13.13. Found: C, 50.52; H, 3.28; N, 13.25. 247 
 248 
iv) (E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl) 249 
-N-cyclohexylacrylamide (4): Mp: 221-223°C. 
1
H NMR (400 MHz, CDCl3) δ 1.11-1.28 250 
(3H, m), 1.32-1.46 (2H, m), 1.59-1.69 (1H, m), 1.60-1.79 (2H, m), 1.94-2.00 (2H, m), 251 
3.83-3.94 (1H, m), 5.71 (1H, br d, J = 8.1 Hz), 6.88 (1H, d, J = 15.6 Hz), 7.32-7.44 (3H, 252 
m), 7.49-7.55 (2H, m) ppm; 
13
C NMR (100 MHz, CDCl3) δ 25.0, 25.7, 33.3, 48.8, 118.7 253 
(q, JC-F = 272 Hz), 120.8, 123.2, 124.5, 127.0, 130.5, 130.7, 131.6, 132.6, 134.0, 146.1, 254 
148.0, 151.0 (q, JC-F = 42 Hz) ppm; 164.5, 164.5. 
19
F NMR (377 MHz, CDCl3) δ -62.42 255 
(3F, s) ppm. Anal. Calcd for C20H18ClF3N4OS: C, 52.81; H, 3.99; N, 12.32. Found: C, 256 
52.82; H, 4.02; N, 12.32. 257 
 258 
v) (E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 259 
N-phenylacrylamide (5): Mp: 222-224°C. 
1
H NMR (400 MHz, CDCl3) δ 7.03-7.15 (2H, 260 
m), 7.29-7.47 (5H, m), 7.50-7.53 (1H, m), 7.57-7.69 (4H, m) ppm; 
13
C NMR (100 MHz, 261 
CDCl3) δ 118.7 (q, JC-F = 272 Hz), 119.9, 120.3, 123.1, 124.6, 126.0, 127.1, 129.2, 130.5, 262 
130.9, 131.4, 132.5, 134.0, 138.1, 146.5, 148.6, 151.3 (q, JC-F = 42 Hz), 163.7 ppm; 
19
F 263 
NMR (377 MHz, CDCl3) δ -62.37 (3F, s) ppm. Anal. Calcd for C20H12ClF3N4OS: C, 264 
53.52; H, 2.69; N, 12.48. Found: C, 53.25; H, 2.88; N, 12.43. 265 
 266 
vi) (E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl) 267 
-N-isopropyl-N-methylacrylamide (6): Mp: 144-145°C. 
1
H NMR (400 MHz, CDCl3) δ 268 
(mixture of rotamers) 1.14 (3.3H, d, J = 6.6 Hz), 1.26 (2.7H, d, J =6.6 Hz), 2.89 (1.35H, s), 269 
2.98 (1.65H, s), 4.27 (0.45H, sep, J = 6.6 Hz), 4.96 (0.55H, sep, J = 6.6 Hz), 7.32-7.53 270 
 12 
(6H, m) ppm; 
13
C NMR (100 MHz, CDCl3) δ (mixture of rotamers) 19.5, 20.7, 26.6, 28.5, 271 
44.6, 28.5, 118.3, 118.5, 118.7 (q, JC-F = 272 Hz), 122.8, 123.7, 125.4, 125.7, 127.1, 130.4, 272 
130.7, 131.7, 132.6, 134.1, 145.9, 146.0, 147.3, 147.6, 150.9 (q, JC-F = 42 Hz), 165.8, 273 
166.1 ppm; 
19
F NMR (377 MHz, CDCl3) δ (mixture of rotamers) -62.81 (1.35F, s), -62.71 274 
(1.65F, s) ppm. Anal. Calcd for C18H16ClF3N4OS: C, 50.41; H, 3.76; N, 13.06. Found: C, 275 
50.43; H, 3.76; N, 12.94. 276 
 277 
vii) (E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl) 278 
-1-(piperidin-1-yl)prop-2-en-1-one (7): Mp: 168-170°C. 
1
H NMR (400 MHz, CDCl3) δ 279 
1.55-1.75 (6H, m), 3.50-3.70 (4H, m), 7.33-7.46 (4H, m), 7.51-7.54 (2H, m) ppm; 
13
C 280 
NMR (100 MHz, CDCl3) δ 24.8, 25.7, 26.9, 43.6, 47.2, 117.6, 118.7 (q, JC-F = 271 Hz), 281 
123.7, 125.8, 127.1, 130.4, 130.7, 131.7, 132.6, 134.1, 145.9, 147.5, 150.9 (q, JC-F = 42 282 
Hz), 165.0 ppm; 
19
F NMR (377 MHz, CDCl3) δ -62.67 (3F, s) ppm. Anal. Calcd for 283 
C19H16ClF3N4OS: C, 51.76; H, 3.66; N, 12.71. Found: C, 51.86; H, 3.81; N, 12.71. 284 
 285 
viii) (E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl) 286 
-1-morpholinoprop-2-en-1-one (8): Mp: 171-172°C. 
1
H NMR (400 MHz, CDCl3) δ 287 
3.60-3.70 (8H, m), 7.35-7.46 (4H, m), 7.52-7.54 (1H, m), 7.60 (1H, d, J = 16.0 Hz) ppm; 288 
13
C NMR (100 MHz, CDCl3) δ 42.7, 46.3, 67.0, 116.1, 118.7 (q, JC-F = 272 Hz), 123.5, 289 
126.7, 127.1, 130.5, 130.8, 131.6, 132.6, 134.0, 146.3, 148.1, 151.2 (q, JC-F = 42 Hz), 290 
165.2 ppm. 
19
F NMR (377 MHz, CDCl3) δ -62.61 (3F, s) ppm. Anal. Calcd for 291 
C18H14ClF3N4O2S: C, 48.82; H, 3.19; N, 12.65. Found: C, 48.67; H, 3.27; N, 12.55. 292 
 293 
ix) (E)-3-(6-(2-Chlorophenyl)-2-(perfluoroethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 294 
N-isopropylacrylamide (9): Mp: 165-166°C. 
1
H NMR (400 MHz, CDCl3) δ 1.22 (6H, d, J 295 
= 6.6 Hz), 4.12-4.27 (1H, m), 5.58 (1H, br d, J = 7.8 Hz), 6.80 (1H, d, J = 15.5 Hz), 296 
7.33-7.48 (3H, m), 7.50-7.58 (2H, m) ppm; 
13
C NMR (100 MHz, CDCl3) δ 22.9, 41.9, 297 
109.3 (tq, J = 256, 41 Hz), 118.0 (qt, JC-F = 285, 36 Hz), 120.6, 123.1, 124.6, 127.1, 130.5, 298 
 13 
130.8, 131.5, 132.6, 134.0, 146.2, 148.0, 150.7 (t, JC-F = 31 Hz), 164.6 ppm; 
19
F NMR 299 
(377 MHz, CDCl3) δ -111.16 (2F, q, JF-F = 2.3 Hz), -84.20 (3F, t, JF-F = 2.3 Hz) ppm. Anal. 300 
Calcd for C18H14ClF5N4OS: C, 46.51; H, 3.04; N, 12.05. Found: C, 46.50; H, 3.08; N, 301 
12.26. 302 
 303 
x) (E)-3-(6-(2-Chlorophenyl)-2-(perfluoropropyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 304 
N-isopropylacrylamide (10): Mp: 170-172°C. 
1
H NMR (500 MHz, CDCl3) δ 1.21 (6H, d, 305 
J = 6.6 Hz), 4.15-4.26 (1H, m), 5.67 (1H, br d, J = 7.8 Hz), 6.82 (1H, d, J = 15.5 Hz), 306 
7.33-7.45 (3H, m), 7.50-7.58 (2H, m) ppm; 
13
C NMR (125 MHz, CDCl3) δ 22.9, 41.9, 307 
105.5-111.2 (m), 111.3 (tt, JC-F = 285, 36 Hz), 117.6 (qt, JC-F = 286, 34 Hz), 120.7, 123.2, 308 
124.6, 127.1, 130.5, 130.7, 131.6, 132.6, 134.1, 146.2, 148.0, 150.6 (t, JC-F = 31 Hz), 309 




F coupling, the signals of the perfluoropropyl group were so 310 
weak that it was difficult to detect those signals and their coupling patterns. 
19
F NMR 311 
(471 MHz, CDCl3) δ -126.61 (2F, t, JF-F = 8.5 Hz), -108.75 (2F, sex, JF-F = 9.4 Hz), -81.01 312 
(3F, t, JF-F = 9.6 Hz) ppm. Anal. Calcd for C19H14ClF7N4OS: C, 44.33; H, 2.74; N, 10.88. 313 
Found: C, 44.18; H, 2.79; N, 10.89. 314 
 315 
xi) (E)-3-(6-(2-Chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-N-isopropylacryl- 316 
amide (11): Mp: 210-212°C. 
1
H NMR (400 MHz, CDCl3) δ 1.19 (6H, d, J = 6.6 Hz), 317 
4.12-4.26 (1H, m), 5.65 (1H, br d, J = 7.6 Hz), 6.92 (1H, d, J = 15.5 Hz) 7.30-7.39 (2H, 318 
m), 7.42-7.47 (1H, m), 7.48-7.57 (2H, m), 8.69 (1H, s) ppm; 
13
C NMR (100 MHz, 319 
CDCl3) δ 22.9, 41.7, 119.5, 122.6, 125.2, 126.9, 130.30, 130.32, 132.2, 132.6, 134.0, 320 
146.2, 147.3, 147.5, 165.1 ppm.
 
HRMS (ESI) m/z: C16H16ClN4OS [M+H]
+
, calcd 321 
347.0728, found 347.0717. 322 
 323 
xii) (E)-3-(6-(2-Chlorophenyl)-2-methylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)-N- 324 
isopropylacrylamide (12): Mp: 214-215°C. 
1
H NMR (400 MHz, CDCl3) δ 1.20 (6H, d, J 325 
= 6.5 Hz), 2.78 (3H, s), 4.20 (1H, m), 5.59 (1H, br d, J = 7.7 Hz), 6.89 (1H, d, J = 15.4 Hz), 326 
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7.28-7.38 (2H, m), 7.40-7.54 (3H, m) ppm; 
13
C NMR (100 MHz, CDCl3) δ 18.0, 23.0, 327 
41.7, 119.1, 122.3, 125.5, 126.9, 130.1, 130.3, 123.4, 132.7, 134.1, 146.2, 147.6, 160.2, 328 
165.3 ppm. Anal. Calcd for C17H17ClN4OS: C, 56.58; H, 4.75; N, 15.53. Found: C, 56.73; 329 
H, 4.65; N, 15.70. 330 
 331 
xiii) (E)-3-(6-(2-Chlorophenyl)-2-(methylthio)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 332 
N-isopropylacrylamide (13):  Mp: 229-230°C. 
1
H NMR (400 MHz, CDCl3) δ 1.19 (6H, 333 
d, J = 6.6 Hz), 2.79 (3H, s), 4.12-4.27 (1H, m), 5.62 (1H, br d, J = 7.7 Hz), 6.80 (1H, d, J 334 
= 15.4 Hz), 7.29-7.38 (2H, m), 7.39-7.55 (3H, m) ppm; 
13
C NMR (100 MHz, CDCl3) δ 335 
16.7, 22.9, 41.7, 119.3, 122.4, 125.4, 126.9, 130.2, 130.3, 132.3, 132.6, 134.0, 145.7, 336 
146.8, 162.6, 165.2 ppm. HRMS (ESI) m/z: C17H18ClN4OS2 [M+H]
+
, calcd 393.0605, 337 
found 393.0594. 338 
 339 
2.1.6. Synthesis of imidazothiadiazole analogs with S(=O)CH3 and SO2CH3 (Scheme 340 
4) 341 
Sheme 4 342 
 343 
i) (E)-3-(6-(2-Chlorophenyl)-2-(methylsulfinyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 344 
N-isopropylacrylamide (14): Compound 13 (394 mg, 1.0 mmol) was dissolved in CH2Cl2 345 
(5 mL) and cooled to 0ºC. To this was added the solution of m-chloroperbenzoic acid 346 
(70%, 246 mg, 1.0 mmol) in CH2Cl2 (5 mL) within 30 min and the mixture was stirred at 347 
room temperature overnight. The reaction was quenched by adding saturated aqueous 348 
Na2CO3 solution (5 mL). The organic layer was washed with saturated aqueous Na2CO3 349 
solution (5 mL) and brine (5mL), and dried over anhydrous Na2SO4. The solvent was 350 
evaporated and the crude product was purified by flash column chromatography (ethyl 351 
acetate 100%) to yield white foam (348 mg, 85%). This was further recrystallized from 352 
CHCl3/hexane to afford white crystals, which were used for the bioassays. Mp: 353 
236-237°C. 
1
H NMR (400 MHz, CDCl3) δ 1.20 (6H, d, J = 6.6 Hz), 3.17 (3H, s), 354 
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4.12-4.28 (1H, m), 5.65 (1H, br d, J = 7.8 Hz), 6.77 (1H, d, J = 15.7 Hz), 7.31-7.47 (3H, 355 
m), 7.47-7.57 (2H, m) ppm; 
13
C NMR (100 MHz, CDCl3) δ 22.9, 41.8, 43.9, 120.1, 122.6, 356 
124.8, 127.1, 130.4, 130.6, 131.8, 132.6, 134.0, 146.8, 147.1, 164.8, 173.5 ppm. HRMS 357 
(ESI) m/z: C17H18ClN4O2S2 [M+H]
+
, calcd 409.0554, found 409.0546. 358 
 359 
ii) (E)-3-(6-(2-Chlorophenyl)-2-(methylsulfonyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 360 
N-isopropylacrylamide (15): Compound 13 (398 mg, 1.0 mmol) was dissolved in 361 
THF/MeOH/water (1:1:1, 15 mL) and cooled to 0ºC. Oxone
®
 (1.84 g, 3.0 mmol) was 362 
slowly added to the solution and the mixture was stirred at 0ºC for 5 min and at room 363 
temperature overnight. After largely evaporating the solvent, the mixture was diluted 364 
with water (20 mL) and extracted with CH2Cl2 (1×10 mL, 2×5 mL). The combined 365 
organic layer was washed with water (10 mL) and brine (10 mL), and dried over 366 
anhydrous Na2SO4. The solvent was evaporated and the crude product was purified by 367 
flash column chromatography (hexane/ethyl acetate = 3:7) to yield a pale yellow solid 368 
(340 mg, 79%). This was further recrystallized from CHCl3/hexane to afford pale yellow 369 
crystals, which were used for the bioassays. Mp: 247-249°C. 
1
H NMR (400 MHz, CDCl3) 370 
δ 1.20 (6H, d, J = 6.6 Hz), 3.45 (3H, s), 4.12-4.27 (1H, m), 5.81 (1H, br d, J = 7.6 Hz), 371 
6.86 (1H, d, J = 15.6 Hz), 7.33-7.47(3H, m), 7.48-7.59 (2H, m) ppm; 
13
C NMR (100 MHz, 372 
CDCl3) δ 22.9, 41.9, 44.0, 120.9, 123.1, 124.4, 127.1, 130.5, 130.8, 131.4, 132.6, 134.0, 373 
147.3, 148.2, 162.1, 164.6 ppm. HRMS (ESI) m/z: C17H18ClN4O3S2 [M+H]
+
, calcd 374 
425.0503, found 425.0492. 375 
 376 
2.1.7. Synthesis of other imidazothiadiazole analogs 377 
 378 
Scheme 5 379 
 380 
i) 3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)-N- 381 
isopropylpropanamide (16): To the solution of (E)-3-(6-(2-chlorophenyl)-2- 382 
 16 
(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)acrylic acid (374 mg, 1.0 mmol) in 383 
MeOH (6 mL) was added hydrazine hydrate (2.0 mL, 41 mmol) and catalytic amount of 384 
acetic acid and saturated aqueous CuSO4 solution. To this, the solution of NaIO4 (1.09 g, 385 
5.1 mmol) in water (10 mL) was added dropwise in 1 hour and the mixture was stirred at 386 
room temperature overnight. After largely evaporating the solvent, the mixture was 387 
diluted with 3 M HCl (20 mL) and extracted with ethyl acetate (3×20 mL). The combined 388 
organic layer was washed with water (20 mL) and brine (20 mL), and dried over 389 
anhydrous Na2SO4. The solvent was evaporated to give the crude propanoic acid. This 390 
was suspended in anhydrous CH2Cl2 (5 mL), and EDC hydrochloride (225 mg, 1.2 mmol) 391 
and catalytic amount of DMAP were added. Then, isopropylamine (98 µL, 1.2 mmol) 392 
was added and the mixture was stirred at room temperature overnight. Because TLC 393 
analysis indicated that the reaction was not complete, EDC hydrochloride (122 mg, 0.64 394 
mmol), isopropylamine (50 µL, 0.61 mmol) and catalytic amount of DMAP were further 395 
added and the mixture was stirred at room temperature for 3 days. The mixture was 396 
diluted with CH2Cl2 (15 mL) and washed successively with saturated aqueous Na2CO3 397 
solution, water, 1 M HCl, water, and brine (10 mL each). The organic layer was dried over 398 
MgSO4 and filtered through a plug of silica gel, which was eluted with ethyl acetate. The 399 
filtrate was concentrated and the crude product was purified by flash column 400 
chromatography (hexane/ethyl acetate = 3:2) to yield a pale yellow solid (86 mg, 21%). 401 
This was further recrystallized from ethyl acetate to afford pale yellow crystals, which 402 
were used for the bioassays. Mp: 180-182°C. 
1
H NMR (400 MHz, CDCl3) δ 1.09 (6H, d, 403 
J = 6.6 Hz), 2.49-2.58 (2H, m), 3.22-3.31 (2H, m), 3.93-4.09 (1H, m), 5.16 (1H, br d, J = 404 
5.4 Hz), 7.32-7.40 (2H, m), 7.42-7.53 (2H, m) ppm; 
13
C NMR (100 MHz, CDCl3) δ 20.6, 405 
22.8, 34.0, 41.6, 118.8 (q, JC-F = 271 Hz), 125.0, 127.1, 130.10, 130.12, 132.5, 132.8, 406 
133.9, 142.2, 142.4, 150.2 (q, JC-F = 42 Hz), 170.0 ppm. 
19
F NMR (377 MHz, CDCl3) δ 407 
-62.63 (3F, s) ppm. Anal. Calcd for C17H16ClF3N4OS: C, 48.98; H, 3.87; N, 13.44. Found: 408 
C, 48.76; H, 4.01; N, 13.26. 409 
 410 
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Scheme 6 411 
 412 
ii) E)-3-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)- 413 
N- isopropylprop-2-enethioamide (17): A mixture of compound 2 (349 mg, 0.84 mmol) 414 
and Lawesson’s reagent (174 mg, 0.43 mmol) in toluene (20 mL) was refluxed for 2 hours. 415 
After cooling, the mixture was filtered through a plug of silica gel, which was eluted with 416 
ethyl acetate. The filtrate was concentrated and the crude product was purified by flash 417 
column chromatography (hexane/ethyl acetate = 3:1) and recrystallization from ethyl 418 
acetate/hexane to yield yellow crystals (282 mg, 78%). Mp: 203-204°C. 
1
H NMR (400 419 
MHz, CDCl3) δ 1.33 (6H, d, J = 6.6 Hz), 4.77-4.91 (1H, m), 7.16-7.26 (2H, m), 7.36-7.49 420 
(3H, m), 7.52-7.58 (1H, m), 7.87 (1H, d, J = 15.1 Hz) ppm. 
13
C NMR (100 MHz, CDCl3) 421 
δ 21.7, 47.6, 118.7 (q, JC-F = 272 Hz), 123.4, 126.6, 126.8, 127.1, 130.6, 130.8, 131.5, 422 
132.6, 133.9, 146.2, 148.7, 151.1 (q, JC-F = 42 Hz), 192.7 ppm; 
19
F NMR (377 MHz, 423 
CDCl3) δ -62.35 (3F, s) ppm. Anal. Calcd for C17H14ClF3N4S2: C, 47.39; H, 3.28; N, 424 
13.00. Found: C, 47.27; H, 3.29; N, 12.86. 425 
 426 
Scheme 7 427 
 428 
iii) (E)-2-(6-(2-Chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4] thiadiazol-5- 429 
yl)-N-isopropylethenesulfonamide (18): To a suspension of lithium chloride (319 mg, 7.5 430 
mmol) and Ph2P(O)CH2SO2NHBoc (1.31 g, 3.3 mmol) in anhydrous CH3CN (25 mL) 431 
was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU; 1.1 mL, 7.4 mmol). To this 432 
solution was added 6-(2-chlorophenyl)-2-(trifluoromethyl)imidazo[2,1-b][1,3,4]- 433 
thiadiazole-5-carbaldehyde (994 mg, 3.0 mmol) and the mixture was stirred at room 434 
temperature for 1.5 h. The resulting suspension was diluted with water (75 mL) and the 435 
pH was adjusted to 3 with 1 M HCl. This was extracted with ether (1×80 mL, 2×40 mL), 436 
and the combined organic layer was washed with brine (100 mL) and dried over 437 
anhydrous MgSO4. The solvent was evaporated and the crude product was purified by 438 
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flash column chromatography (hexane/ethyl acetate = 95:5 – 50:50) to give the N-Boc 439 
vinyl sulfonamide as a pale yellow solid (1.11 g, 73%). 
1
H NMR (400 MHz, DMSO-d6) δ 440 
1.37 (9H, s), 7.24 (1H, d, J = 15.4 Hz), 7.36 (1H, d, J = 15.4 Hz), 7.52-7.62 (3H, m), 441 
7.68-7.72 (1H, m), 11.46 (1H, br s) ppm. 442 
N-Boc vinyl sulfonamide obtained as above (511 mg, 1.0 mmol), isopropanol 443 
(0.19 mL, 2.5 mmol) and triphenylphosphine (668 mg, 2.6 mmol) were dissolved in 444 
anhydrous THF (15 mL). Diethyl azodicarboxylate (DEAD; 40% in toluene; 1.35 mL, 445 
3.1 mmol) was slowly added to the solution and the mixture was stirred at room 446 
temperature for 1 h. The solvent was evaporated and the crude product was purified by 447 
flash column chromatography (hexane/ethyl acetate = 95:5 – 65:35) to give the N-Boc 448 
N-isopropyl vinyl sulfonamide as a pale yellow solid (416 mg, 76%). 
1
H NMR (400 MHz, 449 
CDCl3) δ 1.41 (6H, d, J = 6.9 Hz), 1.54 (9H, s), 4.55 (1H, sep, J = 6.9 Hz), 7.38-7.48 (4H, 450 
m), 7.53-7.58 (1H, m), 7.69 (1H, d, J = 15.5 Hz) ppm. 451 
To a solution of N-Boc N-isopropyl vinyl sulfonamide obtained as above (377 mg, 452 
0.68 mmol) in CH2Cl2 (5 mL) was added trifluoroacetic acid (TFA; 5 mL) and the 453 
mixture was stirred at room temperature for 1 h. The solvent was evaporated and the 454 
crude product was purified by flash column chromatography (hexane/ethyl acetate = 95:5 455 
– 50: 50) to give a white solid (270 mg, 88%). This was further recrystallized from 456 
CHCl3/hexane to afford white crystals, which were used for the bioassays. Mp: 457 
157-158°C. 
1
H NMR (500 MHz, CDCl3) δ 1.21 (6H, d, J = 6.6 Hz), 3.51-3.62 (1H, m), 458 
4.42 (1H, d, J = 7.7 Hz), 7.30 (1H, d, J = 15.4 Hz), 7.35 (1H, d, J = 15.4 Hz), 7.38-7.48 459 
(3H, m), 7.52-7.56 (1H, m) ppm; 
13
C NMR (125 MHz, CDCl3) δ 24.2, 46.4, 118.6 (q, JC-F 460 
= 271 Hz), 120.9, 124.4, 126.2, 127.3, 130.6, 131.1, 131.2, 132.5, 133.8, 147.1, 148.9, 461 
151.9 (q, JC-F = 42 Hz) ppm; 
19
F NMR (471 MHz, CDCl3) δ -62.52 (3F, s) ppm. Anal. 462 
Calcd for C17H14ClF3N4S2: C, 47.39; H, 3.28; N, 13.00. Found: C, 47.27; H, 3.29; N, 463 
12.86. HRMS (ESI) m/z: C16H15ClF3N4O2S2 [M+H]
+
, calcd 451.0272, found 451.0261. 464 
 465 
2.2. Ligand-receptor binding assay 466 
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 Tritiated ponasterone A ([
3
H]PonA, 140 Ci/mmol) was purchased from American 467 
Radiolabeled Chemicals Inc. (St. Louis, MO, USA).  PonA and 20E were purchased 468 
from Cosmo Bio Co., Ltd. (Tokyo, Japan) and Sigma-Aldrich Co. (St. Louis, MO, USA), 469 
respectively. RH-5849 and tebufenozide were from our stock samples. All insect cells are 470 
cultured in our laboratory. Originally, Sf-9 cell line was kindly gifted from Wakenyaku 471 
Co., Ltd. (Kyoto, Japan), NIAS-AeAl2 was given from NIAS Genebank (Tsukuba, 472 
Japan)[14], and BCIRL-Lepd-SL1 was kindly gifted from Dr. Cynthia Goodman 473 
(USDA-ARS, Columbia, MO, USA)[15].  474 
 The ligand binding assay using insect cells was performed as previously reported [16, 475 
17]. In brief, insect cell suspension (400 L; 2 - 3 × 106 cells/mL) was incubated with 476 
DMSO solution of a test compound (1 L) and 70% EtOH solution of [3H]PonA (2 L; 477 
ca. 60,000 dpm) at 25ºC for 30 min. The mixture was diluted with water (3 mL) and 478 
filtered through a glass filter GF-75 (ADVANTEC, Tokyo, Japan). The filter was washed 479 
2 times with water (3 mL), dried, and placed in a vial containing 3 mL of Insta-Gel Plus 480 
(PerkinElmer, Inc., Waltham, MA, USA) to measure the radioactivity with a LSC-6100 481 
liquid scintillation counter (Aloka, Tokyo, Japan). The concentration required for 50% 482 
inhibiton of [
3
H]PonA binding (IC50) was determined by probit analysis[18], and its 483 
reciprocal logarithm, pIC50, was used as the index of binding activity. 484 
 485 
2.3. Larvicidal activity test 486 
Spodoptera litura was kindly provided from Ishihara Sangyo Kaisha, Ltd. 487 
(Kusatsu, Japan). Twenty 3
rd
 instar larvae were put in the glass petri dish with paper filter. 488 
DMSO solution of a test compound (1 L) was applied on the dorsal part of larvae. They 489 
were reared in an insectary at 25ºC. Insecta LFS (Nosan Corporation Life-Tech 490 
Department, Yokohama, Japan) was used to feed larvae. After one week rearing, the 491 
mortality was measured, and 50% lethal dose (LD50) was determined by probit 492 
analysis[18]. Its reciprocal logarithm, pLD50, was used as the index of larvicidal activity. 493 
 494 
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2.4. QSAR analysis 495 
In order to examine the effect of the substituents at 2-position of the 496 
imidazothiadiazole ring, the Hansch-Fujita QSAR analysis was performed using QREG 497 
2.05[19]. ClogP values of synthesized chemicals, which were shown in Table 1, were 498 
calculated by ClogP for Windows Ver. 4.0 (Biobyte Corp., Claremont, CA, USA). In all 499 
equations, the number in parentheses are 95% confidence intervals of each coefficient, n 500 
is the number of compounds used to analyze, s is the standard deviation, and r is the 501 
correlation coefficient, and F is the value of ratio between regression and residual 502 
variances. 503 
 504 
2.5. Receptor modeling and ligand-receptor docking  505 
Since no 3-D structure of Spodoptera frugiperda EcR (SfEcR) is available, we 506 
constructed a 3-D structure model of the ligand binding domain (LBD) of SfEcR from the 507 
X-ray structure of Lepidopteran EcR using a homology modeling software PDFAMS 508 
(In-Silico Sciences Inc., Tokyo, Japan)[20]. We combined two partial primary sequences 509 
of SfEcR (NCBI accession number: AAM54494 and CAD58232)[21, 22] to construct the 510 
primary sequence of SfEcR-LBD. At present four X-ray structures of Lepidopteran EcR 511 
bound to different ligands, namely, PonA (PDB ID: 1R1K) [23], 20E (2R40) [24], a 512 
DAH-type agonist BYI06830 (1R20)[23] and an imidazole-type agonist BYI08346 513 
(3IXP), are available. We used 1R1K, 1R20 and 3IXP as the templates for homology 514 
modeling because the shapes of the ligand binding pockets (LBP) are different among 515 
them. Thus, we obtained three homology models of SfEcR, which were stored as 516 
complexes with PonA, BYI06830 or BYI08346 in order to compare the binding modes. 517 
Ligand-receptor docking was conducted using OMEGA (ver. 2.5.1.4)[25] and 518 
OEDocking (ver. 3.0.1) of Openeye Co. Ltd. (Santa Fe, NM, USA; 519 
http://www.eyesopen.com). First, the LBPs of the SfEcR homology models were defined 520 
using “MAKE RECEPTOR” tool of OEDocking. Next, the mol2 file of ITD (10) was 521 
processed with OMEGA to generate the conformer libraries. Generated conformers are 522 
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aligned in the order of ascending energy and low energy conformers (maximum: 200) 523 
were compiled into a single file as a conformer library. Finally, these conformers were 524 
docked to the LBPs of SfEcR using “FRED”[26] tool of OEDocking. FRED uses 525 
Chemgauss4 scoring function, and this function ranks each binding mode in terms of 526 
shape interactions, hydrogen bonding interactions, metal-chelator interactions, and 527 
desolvation. The binding modes which gave the highest Chemgauss4 scores towards each 528 
LBPs of SfEcR were shown in Fig. 4. 529 
 530 
3. Results 531 
3.1 Synthesis 532 
ITDs were synthesized according to a previously described method with some 533 
modifications [27]. 2-Amino-1,3,4-thiadiazoles bearing CF3, CF2CF3, and CF2CF2CF3 534 
groups were prepared using a reported method [28]. 535 
2-Amino-5-(methylthio)-1,3,4-thiadiazole was also prepared according to a modified 536 
method described in the literature [29]. Formation of the imidazo[2,1-b][1,3,4]thiadiazole 537 
ring was accomplished by simply refluxing 2-amino-1,3,4-thiadiazoles and 538 
2-chlorophenacyl bromide in ethanol. While compounds with electron-withdrawing 539 
substituents (CF3, CF2CF3, and CF2CF2CF3) did not form HBr salts, compounds with 540 
other substituents (H, CH3, SCH3) precipitated as HBr salts in the reaction mixture. In the 541 
next step, imidazothiadiazoles were subjected to the Vilsmeier-Haack reaction to afford 542 
imidazo[2,1-b][1,3,4]thiadiazole-5-carbaldehydes. Next, Knoevenagel condensation of 543 
aldehydes with malonic acid afforded pure (E)-acrylic acids. Finally, condensation of 544 
acrylic acids with various amines yielded ITDs (1–13). In further, compound 13 was 545 
oxidized with m-CPBA and Oxone
®
 to yield sulfoxide 14 and sulfone 15.  546 
Next, we modified the acrylamide moiety. Hydrogenation of the double bond in 547 
the acrylic acid followed by condensation with isopropylamine afforded the 548 
propionamide 16. Hydrogenation using Pd-C or Wilkinson’s catalyst under a hydrogen 549 
atmosphere was unsuccessful, but diimide reduction afforded the desired compound, 550 
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although in poor yield. Compound 2 was successfully converted to thioamide 17 using 551 
Lawesson’s reagent. Vinyl sulfonamide 18 was then synthesized in three steps. First, the 552 
intermediate aldehyde was subjected to the modified Horner-Wittig reaction [30] to 553 
afford the N-Boc vinyl sulfonamide with complete E selectivity. Use of LiCl and DBU 554 
[31] rather than strong bases was essential for preventing product degradation. Next, 555 
N-Boc vinyl sulfonamide was alkylated at the acidic NH group through the Mitsunobu 556 
reaction, and then Boc protecting group was removed by TFA to yield vinyl sulfonamide 557 
18.  558 
 559 
3.2. Ligand binding activity 560 
The biological activities of various ITD analogs are summarized in Table 1. In 561 
terms of the inhibition of [
3
H]PonA incorporation to Sf-9 cells, compound 1 with the 562 
primary acrylamide moiety at the 5-position of the imidazothiadiazole ring was inactive. 563 
However, secondary amides with i-Pr (2), c-Bu (3), and c-Hex (4) were very potent. IC50 564 
values of these compounds were approximately 10–20 nM, which was 10–20 times more 565 
potent than the natural molting hormone 20E (IC50 = 200 nM). The Ph analog (5) was less 566 
potent than the alkyl analogs (2–4) among secondary amides, but equipotent to 20E (19). 567 
Further alkylation (tertiary acrylamide: 6–8) drastically decreased the activity. 568 
Conversion of the oxygen atom of the amide moiety to a sulfur atom (thioamide: 17) did 569 
not have a large impact on activity, but saturation of the olefin moiety (16) decreased 570 
binding by 100-fold. Introduction of a sulfonamide moiety (18) drastically decreased 571 
activity by approximately 1000-fold compared to compound 2. 572 
 573 
Table 1 574 
 575 
Next, the substituent effect at the 2-position of the imidazothiadiazole ring was 576 
examined for CF2CF3 (9), CF2CF2CF3 (10), H (11), CH3 (12), SCH3 (13), S(=O)CH3 (14), 577 
and SO2CH3 (15). By introducing strong electron withdrawing fluorinated alkyl groups 578 
 23 
such as CF3, CF2CF3, and CF2CF2CF3, the activity dramatically increased (more than 579 
1000-fold compared to unsubstituted compound 11). Other electron withdrawing groups 580 
containing a sulfur atom such as S(=O)CH3 and SO2CH3 did not enhance the activity. The 581 
SCH3 group enhanced the activity by 300-fold, although its electronic properties were 582 
equivalent to H in terms of Hammett. The electron-donating CH3 group increased the 583 
activity by only 5-fold. Among TDI congeners, compound 10 showed the highest activity, 584 
which was 3-fold higher than that of PonA and only 3-fold less potent than tebufenozide 585 
in the binding assay against Sf-9 cells. The structure-activity relationship is summarized 586 
in Fig. 3. 587 
 588 
Fig. 3 589 
 590 
 591 
The binding assay was also performed using other insect cell lines, including 592 
Colorado potato beetle cells (BCIRL-Lepd-SL) and Asian tiger mosquito cells 593 
(NIAS-AeAl2). As shown in Table 1, a few compounds showed moderate activity against 594 
mosquito cells, but most compounds were weak or inactive against these cells. 595 
Compound 9 was 2.5-fold more potent than tebufenozide against NIAS-AeAl2, while it 596 
was approximately 30-fold less potent than PonA.  597 
 598 
3.3. Larvicidal activity  599 
Larvicidal activity of the synthesized compounds was measured against S. litura, 600 
which is shown in Table 1. The pLD50 values of compounds 2 and 9 were determined to 601 
be 5.16 and 5.03, respectively, which were approximately 1/20 of tebufenozide, but 602 
5-fold more toxic than RH-5849. 603 
 604 
3.4. QSAR analysis 605 
As shown in Table 1, activity was enhanced by introducing substituents at the 606 
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2-position of the imidazothiadiazole ring. To determine the physicochemical mechanism 607 
of these substituents, binding activity was quantitatively analyzed using substituent 608 
parameters. We previously demonstrated that the hydrophobicity of substituent is 609 
important for the binding of DAHs to the ecdysone receptor of Sf-9 cells [32]. Therefore, 610 
activity was quantitatively analyzed using hydrophobicity ClogP [ClogP (X) – ClogP 611 
(H)] to formulate statistically significant values using Eq. 1.  612 
 613 
pIC50 = 1.326 (±0.772) Clog P + 6.162 (±0.828)   (1) 614 
          n = 8   s = 0.930    r = 0.864   F1,6 = 17.688 615 
 616 
This equation suggests that the hydrophobic interaction between the substituents and the 617 
ligand binding site of the receptor is important for binding. Although the equation was 618 
significant according to the F test and the Clog P term was justified over 99% by t-test, 619 
this correlation equation was not acceptable because of the large standard deviation. 620 
Because the pIC50 value was highly reproducible [32], the value of 0.930 is too large. 621 
Therefore, the addition of another physicochemical parameter to Eq. 1 was considered, 622 
although using two parameters may not be allowed for the analysis of eight compounds (n 623 
= 8). Addition of an electronic parameter (Swain-Lupton F: field effect) drastically 624 
improved the correlation, as shown in Eq. 2, although the standard deviation remained 625 
large (s=0.349).  626 
 627 
   pIC50 = 1.519 (±0. 315) Clog P + 3.923 (±1.643) F + 4.872 (±0.631) (2) 628 
   n = 8   s = 0.349    r = 0.985   F2,5 = 81.754 629 
 630 
These results indicate that the electrostatic interaction between substituents and the 631 
receptor surface surrounding the substituents is important for activity because the 632 
correlation derived using F was better than that using Hammett . Physicochemical 633 
parameter values and calculated pIC50 values from Eq. 2 are listed in Table 2. 634 
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 635 
Table 2.  636 
 637 
4. Discussion 638 
We previously synthesized various non-steroidal ecdysone agonists, including 639 
diacylhydrazine (DAH) [33-35], N-alkyl-3,5-di-tert-butyl-4-hydroxybenzamides 640 
(DTBHIB) [36], tetrahydroquinoline (THQ)[14], oxadiazoline (ODZ) [3], and 641 
-methylene--lactam (GML) (Akahane unpublished), and measured their biological 642 
activity against whole insects, insect tissue, insect cells, and in vitro translated EcR/USP 643 
proteins. Some DAH analogs (tebufenozide, methoxyfenozide, and chromafenozide) 644 
were very potent against lepidopteran tissues and proteins, were equipotent to 645 
ponasterone A, and were moderately potent against dipteran tissues and proteins, but not 646 
potent against Ccoleopteran. In contrast, THQ-type compounds were reported to be 647 
potent against Diptera, particularly mosquitoes [4], but they were not very potent against 648 
Lepidoptera [37]. As shown in Table 1, the selectivity of ITD-type compound 9 was 649 
similar to that of the DAH-type compound 21 (tebufenozide). These results indicate that 650 
the binding mode of ITDs may be similar to that of DAHs, but different from those of 651 
THQs and steroidal agonists.  652 
According to Holmwood and Schindler [9], the binding mode of ITDs differs 653 
from those of PonA and DAHs, but there is no data supporting the binding mode of ITDs. 654 
In contrast, the X-ray crystal structure of the EcR/USP complex bound to an IMD-type 655 
compound can be found in the Protein Data Bank (PDB ID: 3IXP). We performed 656 
docking simulation of ITD compounds to predict the ligand-receptor binding modes, and 657 
two crystal structures of receptor complexes bound to PonA and a DAH-type compound 658 
(BYI06833) were used as template 3-D structures (Fig. 4).  659 
 660 
Fig. 4  661 
 662 
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As shown in Fig. 4, compound 10 fits snugly in the DAH-type pocket. In this 663 
model, the perfluoropropyl group is surrounded by the hydrophobic region of the LBP. 664 
This model is consistent with the results of the QSAR study, which showed that 665 
hydrophobic and electrostatic interactions between the substituents at 2-position and the 666 
receptor surface are important for activity.  667 
Docking simulation of compound 10 was also performed against SfEcR, which 668 
was constructed from the X-ray crystal structure bound to the IMD-type compound (PDB 669 
ID: 3IXP). Although compounds 2 and 9 can dock to the LBP of SfEcR constructed from 670 
3IXP, compound 10 containing the perfluoropropyl group could not be accommodated in 671 
the corresponding pocket. This is likely because of the slightly smaller size of the LBP of 672 
3IXP compared to the DAH binding pocket. Because the protein was treated as a rigid 673 
body in the docking simulation using FRED, the initial size of the ligand binding pocket 674 
is thought to be critical for docking.  675 
As shown above, compound 2 and 9 were moderately toxic to S. litura. The dead 676 
larva of S. liura treated with compound 2 is shown in Fig. 5. In our previous studies, we 677 
synthesized DAH analogs with various substituents at both benzene rings and 678 
quantitatively analyzed the structure-activity relationship to identify the essential 679 
physicochemical properties for larvicidal activity [33, 34]. QSAR equations showed that 680 
when molecular hydrophobicity was high, larvicidal activity against the lepidopteran rice 681 
stem borer Chilo suppressalis was also high. Although the optimum hydrophobicity was 682 
not derived for the DAH-type compounds, which had limited hydrophobicity (varied 683 
A-ring moiety: 2.04–4.68; varied B-ring moiety: 1.99–4.53), there may be an optimum 684 
value for the expanded set of compounds with supra-optimum hydrophobicity. In fact, 685 
optimum hydrophobicity (logPopt = 5.15) was evaluated for activity against C. 686 
suppressalis [38]. Although this insect species was different from S. frugiperda used in 687 
this study, log P values of compounds 4 and 5 exceeded 5.15, suggesting the presence of 688 
optimum hydrophobicity.  689 
 690 
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Fig. 5 691 
 692 
Compound 13 containing the SCH3 group showed relatively high binding activity 693 
(pIC50 = 7.39) against Sf-9 cells, but was not toxic to S. litura. This may be because of the 694 
facile oxidation of the sulfide moiety to sulfone/sulfoxide through metabolism. We 695 
reported that RH-5849 was 10-fold less toxic than tebufenozide against Lepidopteran C. 696 
suppressalis (Pyralidae; pLD50 = 6.27 vs. 7.32) and 100-fold less toxic than tebufenozide 697 
against S. exigua (Noctuidae; pLD50 = 4.91 vs. 7.06) [39]. The difference in pLD50 values 698 
between RH-5849 and tebufenozide was 100-fold against S. litura (Noctuidae), which is 699 
consistent with the toxicity results for S. exigua.   700 
 701 
5. Conclusion 702 
Among 18 synthesized imidazothiadiazole analogs, two compounds with CF2CF3 703 
and CF2CF2CF3 groups showed higher receptor binding activity than ponasterone A 704 
against Lepidoptera Sf-9 cells. The larvicidal activity of the CF2CF3 analog was 705 
determined against S. litura larvae in terms of pLD50. It was 5 times more toxic than 706 
RH5849, but 20 times less potent than tebufenozide. All compounds, however, did not 707 
show strong binding activity against mosquito cells (Diptera) and beetle cells 708 
(Coleoptera). This selective toxicity profile among insect orders is similar to that for 709 
DAHs. In the structure-activity relationship study, a compound with a primary 710 
acrylamide moiety was inactive, but the mono-alkylation of terminal nitrogen of 711 
acrylamides (secondary amides) drastically enhanced the activity. Among secondary 712 
amides, compounds with isopropyl, cyc-butyl and cyc-hexyl groups have similar receptor 713 
binding activity, but the further alkylation (tertiary amide) was detrimental for the 714 
binding. The conversion of amide to thioamide did not have much impact to the activity, 715 
but the saturation of olefin moiety and conversion of amide to sulfonamide were also 716 
detrimental to the activity. QSAR analysis of the substituent effect at 2-position of the 717 
imidazothiadiazole ring indicated that the electron withdrawing and hydrophobic 718 
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substituents at this position are favorable for the ligand-receptor binding.   719 
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Fig. 1. Chemical structures of ecdysone agonists 
 
Fig. 2. Imidazothiadiazole-type compounds synthesized for SAR study 
 
Fig. 3. Summary of structure-activity relationship for the binding activity against Sf-9 
 
Fig. 4. Docking simulation of compound 10 (colored with green) against SfEcR bound to 
PonA (left) and DAH (BYI06833; right). Structure colored with gray is PonA and that 
colored with light brown is BYI06833. Ligand binding domains were modeled from 
1R1K (left) and IR20 (right). 
 










Scheme 2. Construction of (imidazo[2,1-b][1,3,4]thiadiazol-5-yl)acrylic acid moiety: (a) 
EtOH; (b) POCl3, DMF; (c) CH2(COOH)2, piperidine, pyridine 
 
 
Scheme 3. Synthesis of (imidazo[2,1-b][1,3,4]thiadiazol-5-yl)acrylamides: (a) i. (COCl)2, 










Scheme 5. Synthesis of propionamide 16: (a) N2H4, NaIO4, MeOH/H2O (b) 
isopropylamine, EDC, DMAP, CH2Cl2 
 
 
Scheme 6. Synthesis of thioamide 17: (a) Lawesson’s reagent, toluene 
 
 
Scheme 7. Synthesis of vinyl sulfonamide 18: (a) Ph2P(O)CH2SO2NHBoc, LiCl, DBU, 
CH3CN; (b) i-PrOH, DEAD, PPh3, THF; (c) TFA, CH2Cl2 
 
 Table 1. Biological activity of synthesized compounds. 
 
 










 Sf-9 NIAS-AeAl2 BCIRL-Lepd-SL1 S. litura  
1 CF
3
 trans –CH=CH-C(=O)- H H < 4.9 (12%) n.d.a n.d. n.d. 3.56 
2 CF
3
 trans –CH=CH-C(=O)- H i-Pr 8.03d 7.10 4.88 5.16 4.63 
3 CF
3
 trans –CH=CH-C(=O)- H c-Bu 7.71 6.74 ≈ 4.08 (49%) < 4.00 (45%) 4.70 
4 CF
3
 trans –CH=CH-C(=O)- H c-Hex 7.65 6.05 < 4.60 (27%) < 4.30 (10%) 5.82 
5 CF
3
 trans –CH=CH-C(=O)- H Ph 7.08 5.94 < 4.38 (10%) < 4.30 (0%) 5.65 
6 CF
3
 trans –CH=CH-C(=O)- CH
3
 i-Pr 5.20 ≈ 4.38 (51%) < 4.38 (39%) < 4.30 (25%) 4.52 
7 CF
3




- 5.24 ≈ 4.08 (53%) ≈ 4.08 (55%) < 4.48 (0%) 4.88 
8 CF
3








- 5.02 < 4.08 (24%) < 4.08 (17%) < 4.48 (10%) 3.75 
9 CF2CF3 trans –CH=CH-C(=O)- H i-Pr 8.35
e
 7.52 4.72 5.03 5.00 
Table(s)
10 CF2CF2CF3 trans –CH=CH-C(=O)- H i-Pr 8.48 n.d. n.d. n.d. 5.23 
11 H trans –CH=CH-C(=O)- H i-Pr 4.79 n.d. < 4.60 (4.6%) n.d. 3.74 
12 CH
3
 trans –CH=CH-C(=O)- H i-Pr 5.44 < 4.38 (42%) ≈ 4.38 (47%) < 4.30 (0%) 4.24 
13 SCH
3
 trans –CH=CH-C(=O)- H i-Pr 7.39f 6.39 < 4.90 (35%) < 4.30 (0%) 4.44 
14 S(=O)CH
3





 trans –CH=CH-C(=O)- H i-Pr 4.76 > 4.38 (97%) < 4.90 (11%) < 4.30 (0%) 2.26 
16 CF
3
 –CH2-CH2-C(=O)- H i-Pr 5.83 ≈ 4.08 (56%) < 4.08 (25%) < 4.48 (5%) 3.54 
17 CF
3
 trans –CH=CH-C(=S)- H i-Pr 7.51 > 4.60 (99%) < 4.90 (38%) n.d. 4.85 
18 CF3 trans –CH=CH-SO2- H i-Pr 4.98 n.d. n.d. n.d. 4.23 




 n.d. 0.49 
20 20-Hydroxyecdysone 6.78 n.d. 6.36
c
 n.d. -1.72 
21 Tebufenozide 8.81 7.12 5.18 6.47
g
 4.51 





 Not determined 
b
 From Ref. [11] 
c
 Against the in vitro translated EcR/USP heterodimers. From Ref. [40] 
d
 Mean of 7.78, 8.04 and 8.27 
e 
Mean of 8.32 and 8.38 
f
 Mean of 7.37 and 7.40 
g
 Dose-response relationship was derived using ten larvae for each dose.
Table 2. Physicochemical parameters for QSAR calculation and prediction of the binding activity by Eq. 2. 
   
Compounds  Physicochemical parameter  Binding affinity (pIC50) 
No Substituents ClogP F Obsd Calcd (Eq.2)   Δ
a
 
11 H 0.00 0.00 4.79 4.87 -0.08 
12 CH3 0.50 0.01 5.44 5.67 -0.23 
13 SCH3 0.70 0.23 7.39 6.84 0.55 
14 SOCH3 -1.30 0.52 4.79 4.94 -0.15 
15 SO2CH3 -1.48 0.53 4.76 4.70 -0.06 
2 CF3 0.89 0.38 8.03 7.72 0.31 
9 CF2CF3 1.26 0.44 8.35 8.51 -0.16 
10 CF2CF2CF3 1.49 0.42 8.48 8.78 -0.30 
a

























Fig. 4. Docking simulation of compound 10 (colored with green) against SfEcR bound to 
PonA (left) and DAH (BYI06833; right). Structure colored with gray is PonA and that 
colored with light brown is BYI06833. Ligand binding domains were modeled from 















Scheme 2. Construction of (imidazo[2,1-b][1,3,4]thiadiazol-5-yl)acrylic acid moiety: (a) 




 Scheme 3. Synthesis of (imidazo[2,1-b][1,3,4]thiadiazol-5-yl)acrylamides: (a) i. (COCl)2, 












Scheme 5. Synthesis of propionamide 16: (a) N2H4, NaIO4, MeOH/H2O (b) 








Scheme 7. Synthesis of vinyl sulfonamide 18: (a) Ph2P(O)CH2SO2NHBoc, LiCl, DBU, 
CH3CN; (b) i-PrOH, DEAD, PPh3, THF; (c) TFA, CH2Cl2 
 
 
